Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

Nucor shares are rising Wednesday after the steelmaker outlined better second-quarter profit projections than analysts had ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

The deal, announced June 17, includes a cash offer of $10.50 per share for all outstanding Verve stock. Lilly may also pay as ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Global shares are mostly higher and oil prices have slipped as investors await a decision on interest rates by the Federal ...

Deputy DA Andrew Wood ruled Eric Salisbury's fatal shooting of Manuel Garza was justified self-defense, releasing bodycam ...

Energy Stocks Have Had a Mixed Start to 2025. Natural Gas Is Hot and Oil Is Not. Eli Lilly strikes $1.3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say Black boxes analyzed ...